Dupilumab is a fully human monoclonal IgG4 antibody that inhibits the IL-4 and IL-13
signal pathways [
[1]
]. It was approved on March 28, 2017 by US Food and Drug Administration (FDA) for
treatment of moderate to severe atopic dermatitis (AD). It has a good treatment response
with improvements in both physician reported outcome measures such as Eczema Area
Severity Index (EASI) and patient reported outcomes measures such as Dermatology Life
Quality Index (DLQI) and pruritus scores [
[2]
]. Maximal clinical improvement in AD patients treated with dupilumab was seen at
about 4–6 weeks [
[3]
], and improvements in molecular signature of lesional skin was seen at 4 weeks [
[4]
].Abbreviations:
AD (atopic dermatitis), RSOM (raster scanning optoacoustic mesoscopy), CRS (confocal Raman spectroscopy), EASI (Eczema Area Severity Index), DLQI (Dermatology Life Quality Index and TBV, total blood volume)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Dermatological ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.N. Engl. J. Med. 2014; 371: 130-139
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.Lancet. 2017; 389: 2287-2303
- Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.J. Eur. Acad. Dermatol. Venereol. 2018; 32: 850-878
- Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.J. Allergy Clin. Immunol. 2014; 134: 1293-1300
- Three-dimensional multispectral optoacoustic mesoscopy reveals melanin and blood oxygenation in human skin in vivo.J. Biophotonics. 2016; 9: 55-60
- Precision assessment of label-free psoriasis biomarkers with ultra-broadband optoacoustic mesoscopy.Nat. Biomed. Eng. 2017; 1: 1-13
- Impact of filaggrin mutations on Raman spectra and biophysical properties of the stratum corneum in mild to moderate atopic dermatitis.JEADV. 2012; 26: 983-990
- Serum thymus and activation-regulated chemokine (TARC) and interleukin-31 levels as biomarkers for monitoring in adult atopic dermatitis.J. Dermatol. Sci. 2014; 75: 204-207
- Application of photoacoustic methods and confocal microscopy for monitoring of therapeutic response in plaque psoriasis.Skin Pharmacol. Physiol. 2018; 31: 308-315
- Therapeutic pipeline for atopic dermatitis: end of the drought?.J. Allergy Clin. Immunol. 2017; 140: 633-643
Article info
Publication history
Published online: July 12, 2019
Accepted:
July 9,
2019
Received in revised form:
July 8,
2019
Received:
May 31,
2019
Identification
Copyright
© 2019 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.
